Trials / Not Yet Recruiting

Not Yet RecruitingNCT06731959

A Study to Investigate Using Inhaled Fexlamose to Treat Adult Participants Who Have Moderate to Severe COPD

A Phase 2a, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Fexlamose (AER-01) Inhalation Solution in the Treatment of Adults with Moderate to Severe Chronic Obstructive Pulmonary Disease

Status: Not Yet Recruiting
Phase: Phase 2
Study type: Interventional
Enrollment: 100 (estimated)

Sponsor: Aer Therapeutics · Industry
Sex: All
Age: 40 Years – 80 Years
Healthy volunteers: Not accepted

Summary

AER-01-002 is a Phase 2a study being conducted to determine if inhaled fexlamose is an effective and safe treatment for adults with moderate to severe COPD. Study will compare active drug to placebo.

Conditions

COPD

Interventions

Type	Name	Description
DRUG	Flexlamose	Fexlamose solution via nebulizer for 28 days
DRUG	Placebo	Placebo solution via nebulizer for 28 days

Timeline

Start date: 2024-12-01
Primary completion: 2025-11-01
Completion: 2026-01-01
First posted: 2024-12-13
Last updated: 2024-12-13

Source: ClinicalTrials.gov record NCT06731959. Inclusion in this directory is not an endorsement.